Clinical Trial Update: Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With Duchenne Muscular Dystrophy [Phase 2]

View source ↗

Summary

A Phase II double-blind exploratory study of GSK2402968 in ambulant Duchenne muscular dystrophy subjects has completed; results are not detailed in this update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• GSK2402968

Snippet

Sponsor: GlaxoSmithKline | Conditions: Muscular Dystrophies | Phase 2 | Status: COMPLETED